Viz.ai Partners with Sanofi and Regeneron to Improve COPD Care with AI Technology
Wednesday, May 21, 2025
Viz.ai has announced a multi-year collaboration with global healthcare company Sanofi and biotechnology firm Regeneron to support the management of chronic obstructive pulmonary disease (COPD) using artificial intelligence (AI).
COPD is a long-term lung condition that causes breathing difficulties and affects around 392 million people globally. It is currently the fourth leading cause of death worldwide. The condition places a heavy burden on healthcare systems, especially when cases are not managed effectively. Many patients receive suboptimal care due to delays in identifying risk levels, poor care coordination, limited monitoring, and barriers to treatment.
The partnership will focus on evaluating an AI-powered care coordination tool designed to improve detection and treatment for patients with high-risk COPD.
As part of the collaboration, Viz.ai will deploy its COPD module, a digital solution that uses electronic health record (EHR) data and AI to identify patients in need of timely intervention. The technology is intended to assist healthcare providers in streamlining workflows, enabling faster and more efficient care.
The Viz COPD module applies natural language processing to review patient records, helping to screen and prioritise individuals according to clinical guidelines. High-risk cases are flagged for follow-up, aiming to ensure patients receive the care they need sooner. This solution builds on Viz.ai’s existing reach, which includes more than 1,700 hospitals and health systems and over 60,000 healthcare providers.
Through this partnership, Viz.ai, Sanofi, and Regeneron aim to address gaps in COPD care by advancing the use of AI to support earlier intervention and improve outcomes for patients living with this serious respiratory disease.
Source: viz.ai
